• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓性肌萎缩症患者在接受nusinersen 治疗的第一年的最大咬合力 - 一项初步研究。

Maximum bite force in patients with spinal muscular atrophy during the first year of nusinersen therapy - A pilot study.

机构信息

Poliklinik für Kieferorthopädie, Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln, Deutschland.

Zentrum für Seltene Erkrankungen, Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln, Deutschland.

出版信息

Acta Myol. 2020 Jun 1;39(2):83-89. doi: 10.36185/2532-1900-010. eCollection 2020 Jun.

DOI:10.36185/2532-1900-010
PMID:32904902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7460731/
Abstract

OBJECTIVES

Spinal muscular atrophy is a monogenic disease characterized by progressive spinal and bulbar muscle weakness and atrophy. It is caused by the degeneration of alpha-motoneurons. The recent approval of the antisense oligonucleotide nusinersen highlights the need for reliable clinical tools to evaluate motor function in patients with neuromuscular disorders. Measurement of the bulbar neuromuscular function (e.g., bite force) could be an extension to existing motor scales, sensitive to more nuanced changes, especially in symptomatic patients with severely reduced functional abilities.

MATERIALS AND METHODS

Maximum bite force measurement was used to quantify changes of the masticatory function in adult monozygotic female twins with SMA type II. Using piezoelectric transducers, 550 observations were recorded for each patient during the first year of nusinersen therapy.

RESULTS

During the application of four loading doses of nusinersen, bite force levels steadily increased and reached a statistically significantly higher level compared to the initial state in both patients. Subsequent maintenance doses coincided with smaller or no statistically significant changes in maximum bite force.

CONCLUSIONS

This pilot study indicates that the measurement of maximum bite force may be a useful tool to detect changes of the bulbar function in SMA patients. As such, it may supplement existing scales to identify treatment-related changes in motor function.

摘要

目的

脊髓性肌萎缩症是一种单基因疾病,其特征是进行性脊髓和延髓肌肉无力和萎缩。它是由α运动神经元变性引起的。最近反义寡核苷酸 nusinersen 的批准突出了需要可靠的临床工具来评估神经肌肉疾病患者的运动功能。测量延髓神经肌肉功能(例如,咬合力)可以作为现有运动量表的扩展,对更细微的变化更敏感,特别是在功能能力严重下降的有症状患者中。

材料和方法

使用最大咬合力测量来量化 II 型脊髓性肌萎缩症成年同卵双胞胎的咀嚼功能变化。使用压电换能器,在 nusinersen 治疗的第一年中为每位患者记录了 550 次观察。

结果

在应用四个负荷剂量的 nusinersen 期间,咬合力水平稳步升高,与两名患者的初始状态相比,达到了统计学上显著更高的水平。随后的维持剂量与最大咬合力的较小或无统计学显著变化一致。

结论

这项初步研究表明,最大咬合力测量可能是一种有用的工具,可以检测 SMA 患者延髓功能的变化。因此,它可以补充现有的量表,以识别与治疗相关的运动功能变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/200c/7460731/f8bc27a4cb21/am-2020-02-83-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/200c/7460731/934b71f81a10/am-2020-02-83-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/200c/7460731/c059a802f744/am-2020-02-83-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/200c/7460731/f8bc27a4cb21/am-2020-02-83-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/200c/7460731/934b71f81a10/am-2020-02-83-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/200c/7460731/c059a802f744/am-2020-02-83-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/200c/7460731/f8bc27a4cb21/am-2020-02-83-g003.jpg

相似文献

1
Maximum bite force in patients with spinal muscular atrophy during the first year of nusinersen therapy - A pilot study.脊髓性肌萎缩症患者在接受nusinersen 治疗的第一年的最大咬合力 - 一项初步研究。
Acta Myol. 2020 Jun 1;39(2):83-89. doi: 10.36185/2532-1900-010. eCollection 2020 Jun.
2
The Maximum Bite Force for Treatment Evaluation in Severely Affected Adult SMA Patients-Protocol for a Longitudinal Study.重度成年脊髓性肌萎缩症患者治疗评估的最大咬合力——一项纵向研究方案
Front Neurol. 2020 Feb 25;11:139. doi: 10.3389/fneur.2020.00139. eCollection 2020.
3
Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.依库珠单抗对早发性脊髓性肌萎缩症运动、呼吸和球部功能的影响。
Brain. 2023 Feb 13;146(2):668-677. doi: 10.1093/brain/awac252.
4
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.美国脊髓性肌萎缩症的 nusinersen 治疗:回顾性理赔数据库分析结果。
Adv Ther. 2021 Dec;38(12):5809-5828. doi: 10.1007/s12325-021-01938-w. Epub 2021 Oct 28.
5
Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.在德国扩展准入计划中接受 nusinersen 治疗的 1 型 SMA 患儿的评估。
J Neuromuscul Dis. 2018;5(2):135-143. doi: 10.3233/JND-180315.
6
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.依库珠单抗治疗婴儿型脊髓性肌萎缩症的疗效观察
N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.
7
Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.生存、运动功能和运动里程碑:AVXS-101 与 nusinersen 治疗 1 型脊髓性肌萎缩症婴儿的比较。
Adv Ther. 2019 May;36(5):1164-1176. doi: 10.1007/s12325-019-00923-8. Epub 2019 Mar 16.
8
Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.依库珠单抗治疗脊髓性肌萎缩症 1 型 - 波兰扩展准入计划的结果。
Neurol Neurochir Pol. 2021;55(3):289-294. doi: 10.5603/PJNNS.a2021.0020. Epub 2021 Feb 10.
9
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.用nusinersen 治疗婴儿型脊肌萎缩症:一项 2 期、开放标签、剂量递增研究。
Lancet. 2016 Dec 17;388(10063):3017-3026. doi: 10.1016/S0140-6736(16)31408-8. Epub 2016 Dec 7.
10
Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.5q 型脊髓性肌萎缩症成年患者使用 nusinersen 的安全性和治疗效果:一项前瞻性观察研究。
J Neuromuscul Dis. 2019;6(4):453-465. doi: 10.3233/JND-190416.

引用本文的文献

1
Swallowing function in patients with spinal muscular atrophy before and after the introduction of new gene-based therapies: what has changed?脊髓性肌萎缩症患者在引入新的基因疗法前后的吞咽功能:有哪些变化?
Neurol Sci. 2025 Mar;46(3):1137-1149. doi: 10.1007/s10072-024-07883-0. Epub 2024 Dec 4.
2
Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.尽管存在严重运动功能障碍,但利司扑兰可改善非卧床成年5q脊髓性肌萎缩症患者的主观吞咽质量。
J Neurol. 2024 May;271(5):2649-2657. doi: 10.1007/s00415-024-12203-9. Epub 2024 Feb 15.
3

本文引用的文献

1
The Maximum Bite Force for Treatment Evaluation in Severely Affected Adult SMA Patients-Protocol for a Longitudinal Study.重度成年脊髓性肌萎缩症患者治疗评估的最大咬合力——一项纵向研究方案
Front Neurol. 2020 Feb 25;11:139. doi: 10.3389/fneur.2020.00139. eCollection 2020.
2
Orofacial muscles may be affected in early stages of Becker muscular dystrophy: A preliminary study.面颌部肌肉可能在贝克型肌营养不良症早期受到影响:一项初步研究。
Muscle Nerve. 2020 Feb;61(2):213-217. doi: 10.1002/mus.26771. Epub 2019 Dec 24.
3
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Development of an International SMA Bulbar Assessment for Inter-professional Administration.
国际性 SMA 延髓评估工具的制定用于多专业团队管理。
J Neuromuscul Dis. 2023;10(4):639-652. doi: 10.3233/JND-221672.
4
Objective measurement of oral function in adults with spinal muscular atrophy.成人脊髓性肌萎缩症口腔功能的客观测量。
Orphanet J Rare Dis. 2023 May 3;18(1):103. doi: 10.1186/s13023-023-02688-4.
5
Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study.基于人群的脊髓性肌萎缩症患儿中诺西那生钠疗效评估:一项3年随访研究
Brain Commun. 2022 Oct 31;4(6):fcac269. doi: 10.1093/braincomms/fcac269. eCollection 2022.
6
Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen.接受诺西那生治疗的 5q 型脊髓性肌萎缩症 2 型和 3 型成年患者延髓功能评估
Brain Sci. 2021 Sep 20;11(9):1244. doi: 10.3390/brainsci11091244.
7
Bite Force Transducers and Measurement Devices.咬合力传感器与测量装置
Front Bioeng Biotechnol. 2021 Apr 9;9:665081. doi: 10.3389/fbioe.2021.665081. eCollection 2021.
8
Spinal Muscular Atrophy after Nusinersen Therapy: Improved Physiology in Pediatric Patients with No Significant Change in Urine, Serum, and Liquor 1H-NMR Metabolomes in Comparison to an Age-Matched, Healthy Cohort.诺西那生治疗后的脊髓性肌萎缩症:儿科患者生理状况改善,与年龄匹配的健康队列相比,尿液、血清和脑脊液1H-NMR代谢组无显著变化。
Metabolites. 2021 Mar 30;11(4):206. doi: 10.3390/metabo11040206.
依库珠单抗治疗晚发性脊髓性肌萎缩症的疗效观察:一项随机、双盲、安慰剂对照 3 期试验
N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.
4
Advances in therapy for spinal muscular atrophy: promises and challenges.脊髓性肌萎缩症治疗的进展:前景与挑战。
Nat Rev Neurol. 2018 Apr;14(4):214-224. doi: 10.1038/nrneurol.2018.4. Epub 2018 Feb 9.
5
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.脊髓性肌萎缩症的诊断和管理:第 1 部分:诊断、康复、矫形和营养护理建议。
Neuromuscul Disord. 2018 Feb;28(2):103-115. doi: 10.1016/j.nmd.2017.11.005. Epub 2017 Nov 23.
6
Alterations in the Masticatory System in Patients with Amyotrophic Lateral Sclerosis.肌萎缩侧索硬化症患者咀嚼系统的改变。
J Oral Facial Pain Headache. 2018 Winter;32(1):84–90. doi: 10.11607/ofph.1882. Epub 2017 Dec 15.
7
Bite Force Recording Devices - A Review.咬合力记录装置——综述
J Clin Diagn Res. 2017 Sep;11(9):ZE01-ZE05. doi: 10.7860/JCDR/2017/27379.10450. Epub 2017 Sep 1.
8
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.依库珠单抗治疗婴儿型脊髓性肌萎缩症的疗效观察
N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.
9
Quantitative Assessment of Swallowing Dysfunction in Patients with Spinal and Bulbar Muscular Atrophy.脊髓延髓肌萎缩症患者吞咽功能障碍的定量评估
Intern Med. 2017 Dec 1;56(23):3159-3165. doi: 10.2169/internalmedicine.8799-16. Epub 2017 Oct 11.
10
Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review.5号染色体连锁型脊髓性肌萎缩症的患病率、发病率及携带者频率——文献综述
Orphanet J Rare Dis. 2017 Jul 4;12(1):124. doi: 10.1186/s13023-017-0671-8.